News for IMNM Stock

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome to Present at Upcoming Investor Conferences Immunome Reports First Quarter 2025 Financial Results and Provides Business Update Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome Reports Full Year 2024 Financial Results and Provides Business Update Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome to Present at Upcoming March Conferences Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Immunome Announces Pricing of Upsized Public Offering of Common Stock Immunome Announces Proposed Public Offering of Common Stock Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium Immunome Appoints Roee Shahar as Executive Vice President, Commercial Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities Nectin Therapeutics Licenses Novel Antibodies to Immunome Immunome Appoints Phil Tsai as Chief Technical Officer Immunome Announces Completion of Purchase of Assets from Atreca Immunome Announces Promotion of Max Rosett to Chief Financial Officer Immunome Reports First Quarter 2024 Financial Results and Provides Business Update Immunome to Present at 2024 Bank of America Healthcare Conference Immunome Appoints Kinney Horn as Chief Business Officer Immunome Appoints Sandra M. Swain to Board of Directors Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Arrayjet’s ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies Immunome to Participate in the Leerink Partners Global Biopharma Conference Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Immunome Announces Pricing of Public Offering of Common Stock Immunome Announces Proposed Public Offering of Common Stock Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform Immunome Appoints Phil Roberts as Chief Technical Officer Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference Immunome Appoints Carol A. Schafer to Board of Directors Immunome to Acquire Antibody-Related Assets and Materials from Atreca Immunome to Present at the Stifel 2023 Healthcare Conference Immunome Reports Third Quarter 2023 Financial Results Immunome Appoints Jean-Jacques Bienaimé to Board of Directors Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies Immunome Reports Second Quarter 2023 Financial Results Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity Immunome Reports First Quarter 2023 Financial Results Immunome Reports Fourth Quarter and Full Year 2022 Financial Results Immunome to Present at 13th Annual World ADC London Conference Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets Immunome Reports Third Quarter 2022 Financial Results Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer Immunome Reports Second Quarter 2022 Financial Results Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1 Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 Immunome to Present at the Jefferies Healthcare Conference Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant Immunome Reports First Quarter 2022 Financial Results Immunome Reports Fourth Quarter and Full Year 2021 Financial Results FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19 Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 Immunome Reports Third Quarter 2021 Financial Results Immunome to Present at the Stifel Healthcare Conference Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Immunome to Present at the Cantor Global Healthcare Conference Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing Immunome Reports Second Quarter 2021 Financial Results Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors Immunome to Present at the Jefferies Virtual Healthcare Conference Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern Immunome Reports First Quarter 2021 Financial Results Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing Immunome Announces $27 Million Private Placement Immunome Appoints Corleen Roche as Chief Financial Officer Immunome Appoints Dr. Dennis Giesing as Chief Development Officer Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary Immunome Reports Third Quarter 2020 Financial Results and Significant Progress Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering Immunome Announces Pricing of Upsized Initial Public Offering